News

Eli Lilly (NYSE:LLY) Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results
Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 ...
The Straits Times1m
Novo Nordisk obesity shot tied to greater weight loss at lower doses
The company is also testing CagriSema head-to-head with Eli Lilly & Co.’s Zepbound, the obesity drug that’s currently winning ...
STAT13h
Novo Nordisk’s amylin obesity drug keeps performing like Zepbound
Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...
Novo hunts for ‘maximum potential’ from obesity drug CagriSema
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...
Stabroek News22h
China’s Sciwind’s GLP-1 shows similar weight loss to Novo’s Wegovy, study finds
Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of ...
Healio14h
CagriSema superior to placebo for weight loss for obesity with or without diabetes
The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...